2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 353-355
Technology and Procedures, Imaging, Omics Technologies, Bioinformatics, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Microbiome, Diseases, Immunology, GVHD, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

123 Immune injury converts intestinal fibroblasts into a DIO2+IL11+ endocrine niche that drives ISC regeneration in GI-gvhd

Takashi Ikeda, MD, PhD., Akira Yamamoto, MD, PhD.2, Tyler Leach, N/A3, Kelli McCord, PhD4, Lihong Xu, N/A5, Meng-Chih Wu, N/A6, Yuichi Sumii, MD, PhD.7, Neelam Prakash Bodhale, PhD8, Yui Yamamoto, MD, PhD.9, Victoria Ontiveros, N/A10, Ana Santibanez, N/A11, Yaping Sun, MD, PhD.12, Dongchang Zhao, MD, PhD.13, Laure Maneix, PhD14, William Harris Hudson, PhD15, Pavan Reddy, MD16
1 Baylor College of Medicine, Houston, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States
3 Baylor College of Medicine, Houston, Texas, United States
4 Baylor College of Medicine, Houston, Texas, United States
5 Baylor College of Medicine, Houston, Texas, United States
6 Baylor College of Medicine, Houston, Texas, United States
7 Baylor College of Medicine, Houston, Texas, United States
8 Baylor College of Medicine, Houston, Texas, United States
9 Baylor College of Medicine, Houston, Texas, United States
10 Baylor College of Medicine, Houston, Texas, United States
11 Baylor College of Medicine, Houston, Texas, United States
12 Baylor College of Medicine, Houston, Texas, United States
13 Baylor College of Medicine, Houston, Texas, United States
14 Baylor College of Medicine, Houston, Texas, United States
15 Baylor College of Medicine, Houston, Texas, United States
16 Baylor College of Medicine, Houston, Texas, United States

In gastrointestinal graft-versus-host disease (GI-GVHD), allogeneic donor T cells target intestinal stem cells (ISCs) and dismantle the crypt niche, which is required for epithelial repair and regeneration. Whether the injured intestine can form a new niche that drives repair remains unknown. Using a well-characterized BALB/c→B6 model of allogeneic bone marrow transplantation (BMT), we analyzed intact intestines at day 7 after syngeneic (Syn) or allogeneic (Allo) BMT (10 Gy; 2×10⁶ T cells and 5×10⁶ BM cells) with single-cell Xenium spatial transcriptomics. We tested the spatial predictions in GI tissue in vivo, primary fibroblasts, ex vivo organoids, and human immune-mediated disease.

Across 10 mice (2 naïve, 4 Syn, 4 Allo), we decoded 3.1 billion transcripts, segmented 6.2 million cells, and measured 5,056 genes in seven parental lineages and 43 immune subsets. Injury was focal and crypt-centered. We defined the crypt niche as cells within 30 μm of an ISC or transit-amplifying (TA) cell. Allo crypts lost ISCs and Paneth cells, expanded TA cells, and accumulated donor CD4+ and CD8+ T cells and macrophages. Cytotoxic Gzma-high CD8+ T cells expressing Lag3, Tigit, and Pdcd1 crowded ISCs and TA cells. Ligand-receptor analysis detected Gzma-F2rl, Gzma-Pard3, and epithelial nectin-TIGIT interactions only in Allo crypts. TA cells activated apoptosis, ferroptosis, necroptosis, and pyroptosis programs. Homeostatic Wnt, NRG1-ErbB, and midkine signaling declined. Spp1+ reparative macrophages provided osteopontin to TA cells but did not restore the trophic niche. Differential expression required a Benjamini-Hochberg-adjusted P<0.05 and absolute log2 fold change >1.

We next compared matched ileal regions with preserved crypts or severe crypt destruction (4 Syn, 6 Allo, and 3 Allo-severe regions). Severe lesions concentrated cytotoxic CD8+ T cells, fibroblasts, and enteric neurons expressing the sympathetic genes Dbh and Slc18a2. CellChat showed progressive loss of Wnt signaling and enrichment of IL-2 and MAdCAM signaling. Unbiased discovery ranked Dio2 among the transcripts most selectively expressed in severe lesions. DIO2 converts thyroxine (T4) to bioactive triiodothyronine (T3). Dio2 expression remained confined to enteric neurons in Syn and moderately injured Allo tissue, but shifted completely to fibroblasts in areas of severe crypt damage. These fibroblasts co-expressed Il11, Il6, Cxcl5, Cxcl14, Adcy2, and Nptx2. A distinct Grem1+Dio2+ fibroblast subset arose only in severe lesions and linked with T cells, Tregs, B cells, ILC2s, and ILC3s. Dio2+IL11+ fibroblasts localized beside TA cells; significant neighborhoods required a median Z score ≥2 across 100 permutations.

RNAscope confirmed Dio2+Il11+Pdgfra+ fibroblasts in severely damaged Allo crypts, and competitive ELISA showed higher ileal T3 levels in Allo mice than in controls.

We next tested the biological relevance of this novel stromal-endocrine niche. Forskolin (10 μM, 8 h), a direct adenylate cyclase activator, induced Dio2 and Il11 in primary intestinal fibroblasts. T3 (400 nM) induced Ppargc1a in Allo-derived organoids by 4 h. The thyroid hormone receptor antagonist NH-3 (1–10 μM) reduced organoid budding and size, whereas T3 (400 nM–1 μM) increased both. Under IFN-γ stress (100 pg/mL), T3 or IL-11 (1 ng/mL) preserved budding and growth; their combination produced the greatest protection. Forskolin-treated fibroblasts increased organoid growth in co-culture. Each effect was significant (P<0.01–P<0.001). Thus, fibroblasts generate an endocrine niche that supports ISC-dependent regeneration.

RNAscope also identified the DIO2+IL11+ fibroblast-endocrine niche in murine DSS colitis, suggesting a general response to intestinal injury. To assess its human relevance, we analyzed Xenium data from 7 healthy controls, 5 Crohn’s fistulae, and 7 Crohn’s ulcers. DIO2 and IL11 marked lesional Stromal 2 cells located primarily within 50 μm of TA epithelium, recapitulating murine GVHD and DSS colitis.

Immune injury not only damages the ISC niche but also transforms fibroblasts at sites of severe crypt damage into a new local endocrine niche. These fibroblasts activate T4, link T3 with IL-11, and support the regeneration of surviving ISCs and progenitor cells. The DIO2–IL-11 niche represents a promising targeted strategy for repairing GI-GVHD without additional immunosuppression.

 

Takashi Ikeda, MD, PhD.: No relevant conflicts of interest to declare.